Name | (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide |
---|---|
Synonyms |
Pralnaan [INN]
HMR 3480 Pralnaan Pralnaan (USAN/INN) UNII-N986NI319S |
Description | Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment[1][2]. |
---|---|
Related Catalog | |
Target |
Interleukin-1β converting enzyme:1.4 nM (Ki) |
In Vivo | Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment reduces joint damage. Pralnacasan treatment does not appear to affect the weight of the animals[1]. Animal Model: Female Balb/c mice induced with collagenase[1] Dosage: 0 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg Administration: Oral gavage; twice a day; for 6 weeks Result: Significantly ameliorated the histopathological damage of the medial knee joint compartments. |
References |
Density | 1.44g/cm3 |
---|---|
Molecular Formula | C26H29N5O7 |
Molecular Weight | 523.53800 |
Exact Mass | 523.20700 |
PSA | 150.73000 |
LogP | 1.76290 |
Index of Refraction | 1.657 |